¹ Department of Rheumatology, University of Basle, Basle, Switzerland
² Department of Rheumatology and Haematology, University of Tübingen, Tübingen, Germany
³ Department of Haematology, Imperial College Hammersmith Hospital London, London, UK
⁴ St Anna Children’s Hospital, Vienna, Austria
⁵ Department of Haematology, University of Nantes, Nantes, France
⁶ Department of Haematology, University of Basle, Basle, Switzerland
⁷ Department of Medicine, University of Kuopio, Kuopio, Finland
⁸ Department of Haematology, University of Genova, Genova, Italy
⁹ Department of Rheumatology, University of Palermo, Palermo, Italy
¹⁰ Department of Haematology and Rheumatology, University of Heidelberg, Heidelberg, Germany
¹¹ Department of Haematology and Rheumatology, University of Ulm, Ulm, Germany
¹² Department of Haematology, University of Florence, Florence, Italy

Correspondence to:
Correspondence to:
Dr Thomas Daikeler
Department of Rheumatology, University of Basle, Petersgraben 4, CH-4031 Basle, Switzerland; tdaikeler{at}uhbs.ch

Objective: To evaluate the feasibility of haematopoietic stem cell transplantation (HSCT) in vasculitis.

Methods: This is a retrospective analysis of patients who had received HSCT for vasculitic diseases and have been reported to the European League Against Rheumatism autoimmune disease or European Bone Marrow Transplantation ProMISe databases. Information about the disease and outcome was obtained by a questionnaire sent to the referring centres. Response of the disease to HSCT was defined as partial or complete responses according to the ability to reduce immunosuppression after HSCT. In addition, the Medline database was searched for reports on HSCT in patients with vasculitis.

Results: Detailed information was obtained for 15 patients, whose median age at HSCT was 37 years. The diagnoses were cryoglobulinaemia in four patients, Behçet’s disease in three patients, Wegener’s granulomatosis in three patients, and undifferentiated vasculitis, Churg–Strauss angiitis, polychondritis, Takayasu arteritis and polyarteritis nodosa in one patient each. 14 patients received autologous HSCT and 1 an allogeneic HSCT as the first transplant. In three patients, further transplantation was given because of relapse. The overall response, including all consecutive transplantations (HSCT/patient, n = 1–3, median 1.3) to HSCT, was 93%, with 46% complete responses and 46% partial responses; median (range) duration of response at the time of reporting was 45 (16–84) months. Three patients died, one from advanced disease, one from cancer and one from graft-versus-host disease. The Medline search showed five other patients who were effectively treated with HSCT for vasculitic diseases.

Conclusion: This retrospective study suggests that autologous HSCT is feasible for vasculitis. Its value remains to be tested in prospective controlled studies.

Abbreviations: ANCA, antineutrophil cytoplasmic antibody; ATG, antithymocyte globulin; EBMT, European Bone Marrow Transplantation; EULAR, European League Against Rheumatism; G-CSF, granulocyte-colony-stimulating factor; GvHD, graft-versus-host disease; HLA, human leucocyte antigen; HSCT, haematopoietic stem cell transplantation; PAN, polyarteritis nodosa; TNF, tumour necrosis factor

This article has been cited by other articles:

				L Statkute, Y Oyama, W G Barr, R Sufit, S Ho, L Verda, Y Loh, K Yaung, K Quigley, and R K Burt Autologous non-myeloablative haematopoietic stem cell transplantation for refractory systemic vasculitis Ann Rheum Dis, July 1, 2008; 67(7): 991 - 997. [Abstract] [Full Text] [PDF]

				R. K. Burt, Y. Loh, W. Pearce, N. Beohar, W. G. Barr, R. Craig, Y. Wen, J. A. Rapp, and J. Kessler Clinical Applications of Blood-Derived and Marrow-Derived Stem Cells for Nonmalignant Diseases JAMA, February 27, 2008; 299(8): 925 - 936. [Abstract] [Full Text] [PDF]